Therapeutic Progress in Oncology : (Record no. 16386)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07088nam a22004573i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6123265 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724114125.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781119706861 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781786304933 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6123265 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6123265 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1143648942 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC270.8 |
| Item number | .B373 2020 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99406 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Barbet, Jacques. |
| 245 10 - TITLE STATEMENT | |
| Title | Therapeutic Progress in Oncology : |
| Remainder of title | Towards a Revolution in Cancer Therapy? |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (207 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Half-Title Page -- Title Page -- Copyright Page -- Contents -- Preface -- Acknowledgments -- Introduction -- Chapter 1: Genomics and Epigenetics -- Chapter 2: Overview of Cancer Chemotherapy -- Chapter 3: Immunology and the Immune System -- Chapter 4: The Development of Immunotherapy -- Chapter 5: The Maturation of Artificial Intelligence -- Chapter 6: The Evolution of Cancer Therapy -- 1. Genomics and Epigenetics -- 1.1. DNA, RNA and genetic code -- 1.2. Sequencing and genomics -- 1.3. Transcriptome and proteome -- 1.4. Epigenetics8, the missing link -- 2. Overview of Cancer Chemotherapy -- 2.1. The introduction of an innovative method -- 2.2. Nitrogen mustards, the first revival -- 2.3. Anti-metabolites, the potential for chemotherapy finally revealed -- 2.4. Natural products in the first line -- 2.4.1. Antimitotic agents -- 2.4.2. Topoisomerase inhibitors -- 2.5. Cisplatin and organoplatin derivatives -- 2.6. An evolving therapeutic approach -- 2.6.1. Combinatorial chemotherapy -- 2.6.2. Adjuvant chemotherapy -- 2.7. Targeted therapies -- 3. Immunology and the Immune System -- 3.1. From variolation to vaccination -- 3.2. The hegemony of the humoral theory -- 3.2.1. Instructive theory versus selective theory -- 3.2.2. Determining the chemical nature of antibodies -- 3.3. Towards a conciliation between cell theory and humoral theory -- 3.4. A complex and specific mode of action of a so-called adaptive immunity in collaboration with an innate immunity -- 3.4.1. The study of organ transplants for a better understanding of the immune system -- 3.4.2. The predominant role of MHC molecules on T cell reactivity -- 3.4.3. Other membrane molecules with a key role -- 3.4.4. B lymphocytes and antibody production -- 3.4.5. A collaboration with innate immunity -- 3.4.6. Cytokines, immune system messengers. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.5. Summary of innate and adaptive immune responses -- 4. The Development of Immunotherapy -- 4.1. Immunosuppressive treatments for graft tolerance -- 4.2. Hybridoma techniques for the production of monoclonal antibodies -- 4.3. Towards an understanding of the immune response (anti- and pro-tumor) -- 4.3.1. Demonstration of the influence of the immune system on tumor activity -- 4.3.2. From the theory of immune surveillance to the "3 Es" theory -- 4.3.3. Antitumor factors -- 4.3.4. Protumor factors -- 4.4. Antitumor immunotherapy -- 4.4.1. From Coley toxin to bone marrow and hematopoietic stem cell transplantation -- 4.4.2. From T-cell cultures to antitumor vaccines -- 4.4.3. Monoclonal antibodies: from rituximab to immune checkpoint inhibitors (ICI) -- 4.4.4. Radioimmunotherapy -- 4.5. A promising path tending towards improvement -- 5. The Maturation of Artificial Intelligence -- 5.1. From Babbage machines to the universal Turing machine -- 5.2. Cybernetics, for an association between machine and physiology: towards the development of the first neural network -- 5.2.1. Cybernetics... -- 5.2.2. … to connectionism -- 5.2.3. The perceptron, an application of connectionism -- 5.3. Cognitivism and the true emergence of artificial intelligence -- 5.3.1. From the Logic Theorist -- 5.3.2. …to the LISP Language -- 5.4. From optimism to the first crisis -- 5.4.1. AI in a new momentum -- 5.4.2. Technical and theoretical limits finally revealed -- 5.5. Expert systems, a renewed interest in AI -- 5.6. The return of neural networks: an optimal method of automatic learning? -- 5.6.1. A renewal of the structure and method of learning -- 5.6.2. Different types of machine learning -- 5.6.3. A new wave of hope generated by neural networks and other learning techniques -- 5.7. A new crisis before a decisive rebound -- 5.7.1. A technological context not yet adapted. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 5.7.2. A set of factors at the origin of the Big Data era -- 5.8. Deep learning, an association between Big Data and neural networks: AI in another dimension -- 5.8.1. An evolution of structure and power -- 5.8.2. Convolutional networks, surprising performance -- 5.8.3. A wide range of applications as a trigger for investments -- 5.8.4. AI as an aid to oncology -- 6. The Evolution of Cancer Therapy -- 6.1. Cancer surgery -- 6.1.1. Conventional surgery -- 6.1.2. So-called "minimally invasive" surgery -- 6.1.3. Image-guided surgery -- 6.1.4. Cryosurgery -- 6.1.5. Radiofrequency ablation -- 6.1.6. Laser surgery -- 6.1.7. Robotic surgery -- 6.2. External beam radiotherapy (or external beam radiation therapy) -- 6.3. Great innovations in one formula -- 6.4. Genomics and epigenetics -- 6.5. The new therapies of the 21st Century -- 6.5.1. Targeted therapies: the use of small inhibitory molecules (-nib) -- 6.5.2. The use of monoclonal antibodies (mAb) -- 6.5.3. CAR T-cells (Chimeric Antigen Receptor) for customized medicine -- 6.5.4. Vaccine therapies -- 6.5.5. Targeted radionuclide therapy -- 6.6. Theranostics -- 6.6.1. The evolution of medical imaging -- 6.6.2. The theranostic approach, for a predictive and personalized medicine -- 6.7. Artificial intelligence (AI) and Big Data -- 6.8. "In fine" -- Conclusion -- Summary of scientific and technical advances -- Big maneuvers in progress -- "Towards a revolution in cancer therapy?": elements of answers -- Strengths -- Weaknesses -- Opportunities -- Threats -- So, what about the therapeutic revolution? -- List of Abbreviations -- References -- Index -- Other titles from iSTE in Health Engineering and Society -- EULA. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cancer-Treatment. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Foucquier, Adrien. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Thomas, Yves. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Barbet, Jacques |
| Title | Therapeutic Progress in Oncology |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2020 |
| International Standard Book Number | 9781786304933 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6123265">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6123265</a> |
| Public note | Click to View |
No items available.